T. Rowe Price Associates
EPIX

T. Rowe Price Associates’s ESSA Pharma EPIX Stock Holding History

T. Rowe Price Associates’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,832
Closed -$82K – 2948
2022
Q3 		$82K Sell
44,832
-74,619
-62% -$197K ﹤0.01% 2768
2022
Q2 		$376K Hold
119,451
– – ﹤0.01% 2340
2022
Q1 		$738K Buy
+119,451
New +$1.05M ﹤0.01% 2165
2021
Q4 		– Sell
-24,303
Closed -$194K – 2999
2021
Q3 		$194K Hold
24,303
– – ﹤0.01% 2735
2021
Q2 		$694K Buy
+24,303
New +$706K ﹤0.01% 2224

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ABG
Ally Bridge Group New York $101M AUM 249.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return